Drug intelligence / Profile preview

BMN 390

Development stage: Discontinued
Lead developer: BioMarin
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

BMN 390 is an investigational enzyme replacement therapy being developed by BioMarin Pharmaceutical for the treatment of phenylketonuria (PKU). It features a novel pegylation approach using poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA), which is designed to reduce immunogenicity and lower injection viscosity compared to existing therapies such as Palynziq. The drug aims to improve patient experience and safety by minimizing immune reactions associated with traditional polyethylene glycol modifications. As of late 2024, BMN 390 remains in preclinical development, with a targeted Investigational New Drug (IND) application planned for late 2025[1][2][7].

Targets

PAL (Phenylalanine ammonia-lyase)

Beyond the preview

Go deeper on BMN 390.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMN 390.

Explore the full profile